Approval of Marketing Plan and Materials Sample Clauses

Approval of Marketing Plan and Materials. The Contractor shall submit to SCDHHS or its designee all marketing plans and written materials directed at Medicaid eligibles or potential eligibles for approval. These materials include, but are not limited to, materials produced for marketing, member education, evidence of coverage, and grievance procedures. Marketing materials include all types of media including brochures, leaflets, newspapers, magazines, radio, television, billboard and yellow page advertisements directed at Medicaid eligibles or potential eligibles. They also include internet-based materials.
Sample 1
AutoNDA by SimpleDocs
Approval of Marketing Plan and Materials. The Contractor shall submit to SCDHHS or its designee all marketing plans and written materials directed at SCHIP eligibles or potential eligibles for approval. These materials include, but are not limited to: materials produced for marketing, member education, evidence of coverage, member handbook and grievance procedures. Marketing materials include all types of media including brochures, leaflets, newspapers, magazines, radio, television, billboard and yellow page advertisements directed at eligibles or potential eligibles. They also include internet-based materials. 8 POST ENROLLMENT PROCESS The post enrollment process for the SCHIP MCO program shall be as follows:
Sample 1
Approval of Marketing Plan and Materials. The Contractor shall submit to SCDHHS or its designee all marketing plans and written materials directed at Medicaid eligibles or potential eligibles for prior approval. These materials include, but are not limited to, materials produced for marketing, member education, evidence of coverage, and grievance procedures. Marketing materials such as all types of media including brochures, leaflets, newspapers and magazines, and radio, television, billboard and yellow page advertisements directed at Medicaid eligibles or potential eligibles. Marketing materials also include internet-based materials. 8 POST ENROLLMENT PROCESS The post enrollment process for the Medicaid MHN program shall be as follows:
Sample 1
Approval of Marketing Plan and Materials. The Contractor shall submit to SCDHHS or its designee all marketing plans and written materials directed at SCHIP eligibles or potential eligibles for prior approval. These materials include, but are not limited to: materials produced for marketing, member education, evidence of coverage, member handbook and grievance procedures. Marketing materials include all types of media such as brochures, leaflets, newspapers, and magazines, and radio, television, billboard and yellow page advertisements directed at eligibles or potential eligibles. Marketing materials also include internet-based materials and methods of delivery such as Tweeter, etc . 8 POST ENROLLMENT PROCESS The post enrollment process for the SCHIP program shall be as follows:
Sample 1
Approval of Marketing Plan and Materials. The CCN shall submit to DHH or its designee all marketing plans and written materials directed at Medicaid eligibles, current CCN members or potential
Sample 1
Approval of Marketing Plan and Materials. The Contractor shall submit to the Department, or its designee, all marketing plans and written materials directed at Medicaid Eligible or potential Eligible for prior approval. These materials include but are not limited to materials produced for marketing, Medicaid MCO Member education, evidence of coverage, Medicaid MCO Member handbook and grievance procedures. Marketing materials include all types of media such as brochures, leaflets, newspapers, and magazines, and radio, television, billboard and yellow page advertisements directed at Medicaid eligible or potential eligible. Marketing materials also include any electronic mail and internet-based materials. 8 POST ENROLLMENT PROCESS The post enrollment process for the Medicaid MCO Program shall be as follows:
Sample 1
Approval of Marketing Plan and Materials. The Contractor shall submit to SCDHHS or its designee for approval all marketing plans and written materials directed at Medicaid eligibles or potential eligibles. These materials include, but are not limited to, materials produced for marketing, member education, evidence of coverage, and grievance procedures. Marketing materials include all types of media including brochures, leaflets, newspapers, magazines, radio, television, billboard and yellow page advertisements directed at Medicaid eligibles or potential eligibles. For each new Contract period (or extension of existing Contract), the Contractor shall submit no later than sixty (60) calendar days prior to Contract renewal, and for any changes during the contract period no later than sixty (60) calendar days prior to implementation, its marketing plan and materials, including, but not limited to, enrollment/education materials, brochures, fact sheets, posters and lectures to SCDHHS for written approval. The SCDHHS or its designee shall review marketing materials and determine whether to grant approval. In the event SCDHHS or its designee does not respond within thirty (30) working days after the Contractor submits such materials for approval, the Contractor shall notify SCDHHS or its designee for further action.
Sample 1
AutoNDA by SimpleDocs
Approval of Marketing Plan and Materials. Spalding and Licensee will develop mutually acceptable business and marketing plans which address the subjects set forth in Exhibit 9.2, including, types of media for Licensee's advertising and merchandising programs, proposed advertising, promotional, marketing, distribution and sales strategies and targets for the Licensed Products (the "Business and Marketing Plans"). The Marketing Plan shall assign responsibility for completing the actions set forth in the Marketing Plan. Spalding shall have absolute control over the creation and production of advertising, promotional, merchandising and other marketing materials for which Spalding is responsible. Spalding shall approve in advance all advertising, promotional, merchandising and other marketing materials for which Licensee is responsible, including without limitation: (i) all containers, packaging, labels, tags and the like; (ii) all advertising, promotional, merchandising and other marketing materials; (iii) all stationery, business cards and invoices; and (iv) all other transaction documents and business materials. Licensee shall submit such materials in their proposed final form to Spalding at least thirty (30) business days before the proposed publication or release of such materials.
Sample 1

Related to Approval of Marketing Plan and Materials

  • Promotional Materials In the event that the Fund or the Adviser makes available any promotional materials related to the Securities or the transactions contemplated hereby intended for use only by registered broker-dealers and registered representatives thereof by means of an Internet web site or similar electronic means, the Adviser will install and maintain, or will cause to be installed and maintained, pre-qualification and password-protection or similar procedures which are reasonably designed to effectively prohibit access to such promotional materials by persons other than registered broker-dealers and registered representatives thereof.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Manufacturing and Marketing Rights The Company has not granted rights to manufacture, produce, assemble, license, market, or sell its products to any other person and is not bound by any agreement that affects the Company's exclusive right to develop, manufacture, assemble, distribute, market, or sell its products.

  • Regulatory Materials (a) Alvogen shall have the sole right to control filing or submission of Regulatory Materials with the Regulatory Agencies in the Territory with respect to Product including the MAA Approval for Product and Regulatory Approvals in the Territory, subject to Section 3.2 and the oversight of and in consultation with the Executive Steering Committee, and [***]Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. shall be responsible for managing all communications and interactions with the Regulatory Agencies in the Territory with respect to Product in the Territory. In all cases, prior to the filing of any Regulatory Materials (including the MAA for Product) for Product with the applicable Regulatory Agency, Alvogen shall provide a copy thereof to Pfenex (through the Executive Steering Committee) for its review and comment. Pfenex shall have fifteen (15) Business Days from the date it receives a copy of any Regulatory Materials with respect to the Product to provide Alvogen with comments regarding such Regulatory Materials, unless the Regulatory Agencies in the Territory or Applicable Law requires that such Regulatory Material(s) be filed on a timeline that does not reasonably permit such advanced notice, in which case Pfenex shall have as much time as is reasonably practicable to provide Alvogen with comments. Alvogen shall consider all such comments in good faith. Alvogen shall, to the extent permitted by Applicable Law, provide Pfenex with (i) reasonable advanced notice (and in no event less than fifteen (15) Business Days’ advance notice whenever feasible) of substantive meetings with any Regulatory Agency in the Territory that are either scheduled with or initiated by or on behalf of Alvogen or its Affiliates, (ii) an opportunity to have a reasonable number (but at least two (2)) representatives participate in all substantive meetings with the Regulatory Agencies in the Territory with respect to Product, and in any case keep Pfenex informed as to all material interactions with the Regulatory Agencies in the Territory with respect to Product, and (iii) a copy of any material documents, information and correspondence submitted to or received from the Regulatory Agencies in the Territory with respect to Product as soon as reasonably practicable.

  • Advertising and Promotional Materials The Purchaser acknowledges and agrees that the Vendor shall have the right to use drawings, photographs, videos or other depictions of the interior and/or exterior of the Dwelling and/or the Subdivision or any components or features thereof in any promotional or advertising materials without notice to or consent from the Purchaser being required in any manner whatsoever.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Marketing Materials (a) During the term of this Agreement, the Sub-Adviser agrees to furnish the Manager at its principal office for prior review and approval by the Manager all written and/or printed materials, including but not limited to, PowerPointÒ or slide presentations, news releases, advertisements, brochures, fact sheets and other promotional, informational or marketing materials (the “Marketing Materials”) for internal use or public dissemination, that are produced or are for use or reference by the Sub-Adviser, its affiliates or other designees, broker-dealers or the public in connection with the Series, and Sub-Adviser shall not use any such materials if the Manager reasonably objects in writing within five business days (or such other period as may be mutually agreed) after receipt thereof. Marketing Materials may be furnished to the Manager by first class or overnight mail, facsimile transmission equipment, electronic delivery or hand delivery.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Commercialization Plans As soon as practicable after formation of the JCC (following Acucela’s exercise of an Opt-In Right under Section 3.1), the JCC shall prepare and approve the initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation (and, if applicable, any New Formulation or Other Indication Product) in the Territory. The Parties shall use Commercially Reasonable Efforts to ensure that such initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation is consistent with the general Commercialization Plan outline set forth in Exhibit C attached hereto and incorporated herein (the “General Commercialization Plan Outline”). The JCC shall prepare and approve a separate Commercialization Plan for Commercialization of Licensed Product for the Initial Indication in the Initial Formulation in the Territory and for Commercialization of each Other Indication Product and New Formulation (if any) in the Territory, and shall update and amend each Commercialization Plan not less than annually or more frequently as needed to take into account changed circumstances or completion, commencement or cessation of Commercialization activities not contemplated by the then-current Commercialization Plan. Amendments and revisions to the Commercialization Plan shall be reviewed and discussed, in advance, by the JCC, and Otsuka agrees to consider proposals and suggestions made by Acucela regarding amendments and revisions to the Commercialization Plan. Any amendment or revision to the Commercialization Plan that provides for an increase or decrease in the number of FTEs for any Phase 3b Clinical Trials or Post-Approval Studies as compared to the previous version of the Commercialization Plan, or that provides for addition or discontinuation of tasks or activities as compared to the previous version of the Commercialization Plan, or that moves forward the timetable for activities reflected in the Commercialization Plan, shall provide for a reasonable ramp-up or wind-down period, as applicable, to accommodate a smooth and orderly transition of Commercialization activities to the amended or revised Commercialization Plan. Each Commercialization Plan shall identify the goals of Commercialization contemplated thereunder and shall address Commercialization (including Co-Promotion) activities related to the Licensed Product (including, if applicable, any Other Indication Product), including:

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!